Complete VTVT Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
VTVT DCF Analysis
VTVT (vTv Therapeutics Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | $1.0M | $915.3K | $823.8K | $741.4K | $667.3K | $600.5K |
| Revenue Growth % | - | -100.0% | Infinity% | -10.0% | -10.0% | -10.0% | -10.0% | -10.0% |
| EBIT | $-22.5M | $-25.5M | $-24.2M | $45.8K | $41.2K | $37.1K | $33.4K | $30.0K |
| EBIT Margin % | -1116.9% | 0.0% | -2377.6% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $-16.9M | $-19.1M | $-18.1M | $34.3K | $30.9K | $27.8K | $25.0K | $22.5K |
| NOPAT Margin % | -837.7% | -Infinity% | -1783.2% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% |
| Capex | $21.0K | $0 | $0 | $9.2K | $8.2K | $7.4K | $6.7K | $6.0K |
| Capex / Revenue % | 1.0% | NaN% | 0.0% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% |
| Depreciation | $92.0K | $90.0K | $89.0K | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| D&A / Revenue % | 4.6% | Infinity% | 8.8% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Change in NWC | $12.3M | $-19.3M | $32.9M | $0 | $0 | $0 | $0 | $0 |
| NWC Change / Revenue % | 607.7% | -Infinity% | 3232.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Unlevered FCF | $-29.1M | $311.5K | $-50.9M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| UFCF % Chg. | - | 101.1% | -16448.3% | Infinity% | NaN% | NaN% | NaN% | NaN% |
| FCF / Revenue % | -1441.9% | Infinity% | -5007.4% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Discount Factor | - | - | - | 0.935 | 0.874 | 0.817 | 0.764 | 0.715 |
| Present Value of FCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| Sum of PV of UFCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.9% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.2% |
| Risk Free Rate | 4.37% |
| Market Risk Premium | 4.3% |
| Beta | 0.60 |
| Cost of Equity | 7.0% |
| Total Debt | $169.0K |
| Market Cap | $42.4M |
| Total Capital | $42.6M |
| Debt Weighting | 0.4% |
| Equity Weighting | 99.6% |
| WACC | 7.0% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $InfinityB |
| Terminal Value | $InfinityB |
| PV of Terminal Value | $InfinityB |
| Cumulative PV of UFCF | $InfinityB |
| Net Debt | $-36.6M |
| Equity Value | $InfinityB |
| Shares Outstanding | 5.8M |
| Implied Share Price | $InfinityB |
| Current Share Price | $16 |
| Implied Upside/(Downside) | +Infinity% |
Valuation Summary
$Infinity
Implied Price
$16.20
Current Price
+Infinity%
Upside/Downside
7.0%
WACC
VTVT Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 8 peer companies in Healthcare
P/E Ratio
$0.00
-100.0%
Peer Median: 0.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$0.00
-100.0%
Peer Median: 0.6x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for VTVT's business model and current situation.
Multiple Comparison
| Multiple | VTVT Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -5.7x | 0.0x | 0.0x | -Infinity% | Undervalued |
| EV/EBITDA | Infinityx | 0.0x | 0.0x | Infinity% | Overvalued |
| P/S Ratio | 2494.0x | 0.6x | 2.3x | 444789.3% | Overvalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.05B | 0.0x | 0.0x | 46.9x | |
| $0.09B | 0.0x | 0.0x | 74.8x | |
| $0.06B | 0.0x | 0.0x | 522.2x | |
| $0.04B | 0.0x | 0.0x | 2494.0x | |
| $0.06B | 0.0x | 0.0x | 0.6x | |
| $0.05B | 0.0x | 0.0x | 5.8x | |
| $0.05B | 0.0x | 0.0x | 0.5x | |
| $0.06B | 0.0x | 0.0x | 0.0x |